Navigation Links
Hypocalcemia in Medical Technology

First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival

... certain oncology indications. Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast ... by the prescriber prior to initiation of bisphosphonate treatment. hypocalcemia may occur with Reclast therapy. All patients with Paget's disease should ...

Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis

... certain oncology indications. Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast ... by the prescriber prior to initiation of bisphosphonate treatment. hypocalcemia may occur with Reclast therapy. In the Pivotal Fracture Trial an increased ...

New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis

... in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... cases, intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis

... osteoporosis. Reclast is contraindicated in patients with hypocalcemia (low blood calcium), hypersensitivity to zoledronic acid and in women who ... already being treated with Zometa should not be treated with Reclast. hypocalcemia may occur with Reclast therapy. All patients with Paget's disease should ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

... Grade 4 lymphopenia, neutropenia and thrombocytopenia were observed in 1, 2 and 2 patients, respectively. Grade 1-3 anemia, nausea/vomiting and hypocalcemia were observed in 18, 1, and 3 patients, respectively. “Myelosuppression, particularly neutropenia, is a substantial clinical problem in ...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...
Other Contents
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
(Date:5/28/2015)... Medical Device Cybersecurity Quality Assurance: ... Webinar**, June 23, 2015 — 1:00 p.m. – ... connectivity opens up a wealth of possibilities for ... of potential liabilities. Devices transmit data on the ... be sure the information doesn’t fall into unauthorized ...
(Date:5/28/2015)... CA (PRWEB) May 28, 2015 Cosmetic ... of plastic surgeons and patients alike. You can find ... breast augmentation, and body contouring. Readers can directly connect ... streamlined user experience from the ground up. , The ... is allowing the community to grow and getting it ...
(Date:5/28/2015)... 28, 2015 AMVETS National Executive Director ... Commission on Care established by Congress to examine how ... , Appointed to the commission by Mitch McConnell, majority ... one of only 15 voting members on the panel, ... Accountability Act of 2014. The goal of the commission ...
(Date:5/28/2015)... On Sunday, June 21, 2015, Colorado residents will participate ... the strength, passion and endurance of those facing Alzheimer’s ... this sunrise-to-sunset event symbolizes the challenging journey of those ... funds and awareness to advance the care, support and ... encouraged to create their own experience as they fundraise ...
(Date:5/28/2015)... NJ (PRWEB) May 28, 2015 Three years ... new location for his Shore Vascular & Vein Center! ... the circulatory system. It is his mission to provide ... and respect. , Dr. Jeffrey Gosin is Board ... of the University of Pennsylvania and Jefferson Medical College. He ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 2Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 3Health News:New York Cosmetic Doctors Now in Cosmetic Town 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 3Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3
Other TagsOther Tags